A01=Board on Health Care Services
A01=Board on Health Sciences Policy
A01=Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials
A01=Institute of Medicine
Age Group_Uncategorized
Age Group_Uncategorized
Author_Board on Health Care Services
Author_Board on Health Sciences Policy
Author_Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials
Author_Institute of Medicine
automatic-update
B01=Christine M. Micheel
B01=Gilbert S. Omenn
B01=Sharly J. Nass
Category1=Non-Fiction
Category=PSD
COP=United States
Delivery_Delivery within 10-20 working days
eq_bestseller
eq_isMigrated=2
eq_nobargain
eq_non-fiction
eq_science
Language_English
PA=Available
Price_€50 to €100
PS=Active
softlaunch
Product details
- ISBN 9780309224185
- Dimensions: 152 x 229mm
- Publication Date: 13 Aug 2012
- Publisher: National Academies Press
- Publication City/Country: US
- Product Form: Paperback
- Language: English
Secure
checkout
Fast Shipping
Easy returns
Technologies collectively called omics enable simultaneous measurement of an enormous number of biomolecules; for example, genomics investigates thousands of DNA sequences, and proteomics examines large numbers of proteins. Scientists are using these technologies to develop innovative tests to detect disease and to predict a patient's likelihood of responding to specific drugs. Following a recent case involving premature use of omics-based tests in cancer clinical trials at Duke University, the NCI requested that the IOM establish a committee to recommend ways to strengthen omics-based test development and evaluation. This report identifies best practices to enhance development, evaluation, and translation of omics-based tests while simultaneously reinforcing steps to ensure that these tests are appropriately assessed for scientific validity before they are used to guide patient treatment in clinical trials.
